

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Attorney Docket Number	5759-67433-01
Application Number	10/727,109
Filing Date	December 2, 2003
First Named Inventor	Normand
Art Unit	1632
Examiner Name	Jane J. Zara

**U.S. PATENT DOCUMENTS**

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		6,251,398	6.26.2001	O'Hare et al.
		6,342,229	1.29.2002	O'Hare et al.
		6,521,455	2.18.2003	O'Hare et al.
		6,734,167	5.11.2004	O'Hare et al.
		7,067,632	6.27.2006	Elliott

**OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
		Zavaglia et al., "VP22-Mediated and Light-Activated Delivery of an Anti-c-raf1 Antisense Oligonucleotide Improves its Activity after Intratumoral Injection in Nude Mice," <i>Molecular Therapy</i> , Vol. 8, No. 5, 6 pages, (November 2003).
		Normand et al., "Particle Formation by a Conserved Domain of the Herpes Simplex Virus Protein VP22 Facilitating Protein and Nucleic Acid Delivery," <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 18, pages 15042-15050, (May 2001).
		Normand et al., "VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo," <i>Molecular Vision</i> , pages 184-191, (2005).

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.